All Press Releases for March 31, 2021

Karl Willert, PhD, Lauded for Excellence in Scientific Research

Dr. Willert researches stem cell biology and cancer at the University of California San Diego



    DEL MAR, CA, March 31, 2021 /24-7PressRelease/ -- Karl Willert, PhD, has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Driven by his scientific curiosity, Dr. Willert earned a Bachelor of Science in biochemistry from the University of California San Diego (UCSD) in 1989. Upon graduating, he pursued a Doctor of Philosophy in the same discipline, which he completed in 1996 at the University of California San Francisco. Following this accomplishment, he became a postdoctoral fellow at Stanford University School of Medicine, where he served for the following six years. Throughout the course of his career, Dr. Willert gained valuable expertise in the field as a visiting scientist with the Scripps Research Institute, a scientist with Cellerant Therapeutics and Targeted Molecules and an assistant professor at UCSD.

Supported by his considerable expertise in biochemistry, stem cell biology, early human development and cancer development, Dr. Willert presently excels as a professor at UCSD and as the director of the University's Human Embryonic Stem Cell Core Facility. His primary research interests focus on an important class of developmental regulators, called WNT. These WNT genes are critical to normal embryonic development of all animals, and defects in these genes are associated with a host of pathological states, especially cancer. Moreover, Dr. Willert frequently reviews manuscripts for many highly cited scientific journals and grants for national and international organizations, such as the National Institute of Health, Cancer Research UK, the Czech Science Foundation, the Israel Ministry of Science and Technology, the Dutch Cancer Society and the German Research Foundation (DFG).

In light of his professional expertise, Dr. Willert has mentored a plethora of doctoral and Masters students and post-doctoral fellows, and has been invited to speak at seminars at numerous international scientific meetings and universities, including Vanderbilt University, the University of California, Santa Barbara, the University of Heidelberg and at Kyoto University. Along with other scholars in the field, he has also contributed to such publications as "Wnt proteins are lipid-modified and can act as stem cell factors," "A rare human syndrome provides genetic evidence that WNT signaling is required for reprogramming of fibroblasts into induced pluripotent stem cells" and "EGFR is required for Wnt9a/Fzd9b signalling specificity." Looking toward the future, Dr. Willert intends to continue his research and edification at the University of California San Diego. Ultimately, he aims to shepherd many of his projects into a clinical development stage.

About Marquis Who's Who®
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® now publishes many Who's Who titles, including Who's Who in America®, Who's Who in the World®, Who's Who in American Law®, Who's Who in Medicine and Healthcare®, Who's Who in Science and Engineering®, and Who's Who in Asia®. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.

# # #

Contact Information

-- --
Marquis Who's Who Ventures LLC
Uniondale, NY
USA
Voice: 844-394-6946
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us: